Jefferies Group reiterated their buy rating on shares of TherapeuticsMD Inc (AMEX:TXMD) in a research note issued to investors on Tuesday. The firm currently has a $18.00 price target on the stock.

Separately, Oppenheimer Holdings Inc. started coverage on TherapeuticsMD in a research report on Tuesday. They set an outperform rating for the company.

Shares of TherapeuticsMD (AMEX:TXMD) opened at 7.31 on Tuesday. TherapeuticsMD has a one year low of $4.39 and a one year high of $11.26. The firm has a 50-day moving average price of $6.26 and a 200 day moving average price of $7.34. The stock’s market capitalization is $1.44 billion.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of US and international trademark & copyright law. The original version of this article can be accessed at

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.